Evidence map›Paper›PMID 36002611›Full record

ArticlePharmaceutical research2023

Optimized Cationic Lipid-assisted Nanoparticle for Delivering CpG Oligodeoxynucleotides to Treat Hepatitis B Virus Infection.

Yi-Fang Chen, Yan Wang, Yue Wang, Ying-Li Luo, Zi-Dong Lu, Xiao-Jiao Du, Cong-Fei Xu, Jun Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yi-Fang ChenSchool of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, 511442, People's Republic of China.
Yan WangSchool of Medicine, South China University of Technology, Guangzhou, 510006, People's Republic of China.
Yue WangSchool of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, 511442, People's Republic of China.
Ying-Li LuoSchool of Medicine, South China University of Technology, Guangzhou, 510006, People's Republic of China.
Zi-Dong LuSchool of Medicine, South China University of Technology, Guangzhou, 510006, People's Republic of China.
Xiao-Jiao DuSchool of Medicine, South China University of Technology, Guangzhou, 510006, People's Republic of China. duxjz@scut.edu.cn.
Cong-Fei XuSchool of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, 511442, People's Republic of China. xucf@scut.edu.cn.ORCID http://orcid.org/0000-0002-6291-5711
Jun WangSchool of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, 511442, People's Republic of China.
South China University of Technology · CN

Funding

Guangdong Basic and Applied Basic Research Foundation 2019A1515011878Guangdong Basic and Applied Basic Research Foundation 2022B1515020025Guangdong Provincial Pearl River Talents Program 2017GC010482Guangdong Provincial Pearl River Talents Program 2017GC010713National Natural Science Foundation of China 32071378National Natural Science Foundation of China 81901875National Natural Science Foundation of China 82072048Science and Technology Program of Guangzhou, China 202103030004
6 · The paper itself

Abstract

purposeHepatitis B virus (HBV) infection is such a global health problem that hundreds of millions of people are HBV carriers. Current anti-viral agents can inhibit HBV replication, but can hardly eradicate HBV. Cytosine-phosphate-guanosine (CpG) oligodeoxynucleotides (ODNs) are an adjuvant that can activate plasmacytoid dendritic cells (pDCs) and conventional dendritic cells (cDCs) to induce therapeutic immunity for HBV eradication. However, efficient delivery of CpG ODNs into pDCs and cDCs remains a challenge. In this study, we constructed a series of cationic lipid-assisted nanoparticles (CLANs) using different cationic lipids to screen an optimal nanoparticle for delivering CpG ODNs into pDCs and cDCs.

methodsWe constructed different CLAN

resultsWe found that CLAN fabricated with 1,2-Dioleoyl-3-trimethylammonium propane (DOTAP) showed the highest efficiency for delivering CpG ODNs into pDCs and cDCs, resulting in strong therapeutic immunity in HBV-carrier mice. By using CLAN

conclusionWe screened an optimized CLAN fabricated with DOTAP for efficient delivery of CpG ODNs to pDCs and cDCs, which can act as a therapeutic vaccine adjuvant for treating HBV infection.

Indexed as

Hepatitis BNanoparticlesAdjuvants, ImmunologicAnimalsCytosineDendritic CellsFatty Acids, MonounsaturatedGuanosineHepatitis B virusMiceOligodeoxyribonucleotidesPhosphatesQuaternary Ammonium Compounds1,2-dioleoyloxy-3-(trimethylammonium)propaneAdjuvants, ImmunologicCytosineFatty Acids, MonounsaturatedGuanosineOligodeoxyribonucleotidesPhosphatesQuaternary Ammonium CompoundsCationic lipidCpG ODNsHBVPolymeric nanoparticleVaccine

Identifiers

PMID36002611
OpenAlexW4293105631

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.